GlassScriptPhysician profile
Callie Seybert
NPI 1326506718
$3,813.01
in general payments reported to CMS, 2019-2025
54 companies · $440 in 2025
The $440 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,069 · 2023: $842 · 2024: $1,463 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,669 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,669.43 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $537.47 | 2022-2025 | |
| Genentech USA, INC. | $243.37 | 2023-2025 | Lunsumio, Polivy, Columvi |
| Regeneron Healthcare Solutions, INC. | $194.41 | 2022-2024 | Libtayo |
| Amgen INC. | $182.46 | 2022-2023 | Blincyto, Kyprolis |
| Astellas Pharma US INC | $177.20 | 2022-2024 | Xtandi, Padcev |
| Takeda Pharmaceuticals U.S.A., INC. | $146.19 | 2022-2025 | Fruzaqla, Iclusig |
| Beigene USA, INC. | $135.46 | 2022-2025 | Brukinsa |
| Astrazeneca Pharmaceuticals LP | $132.16 | 2022-2025 | Lynparza, Imfinzi, Calquence |
| Sobi, INC | $122.68 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $114.66 | 2022-2024 | |
| Abbvie INC. | $107.19 | 2024-2025 | |
| Tersera Therapeutics LLC | $102.35 | 2022-2024 | Zoladex |
| Alexion Pharmaceuticals, INC. | $94.00 | 2022-2025 | Ultomiris |
| Pharmaessentia USA Corporation | $89.32 | 2022-2024 | Besremi |
| Incyte Corporation | $88.91 | 2022-2025 | Jakafi |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Legend Biotech USA INC. | $86.08 | 2024 | |
| Merck Sharp & Dohme LLC | $79.32 | 2023-2024 | Keytruda, Lynparza |
| Lilly USA, LLC | $75.98 | 2022-2024 | Verzenio, Jaypirca, Retevmo |
| Daiichi Sankyo INC. | $71.11 | 2022-2024 | Injectafer, Enhertu |
| Emd Serono, INC. | $67.80 | 2022-2024 | |
| Ipsen Biopharmaceuticals, INC | $63.80 | 2022 | |
| Eisai INC. | $56.89 | 2022-2025 | |
| Glaxosmithkline, LLC. | $52.21 | 2023-2024 | Jemperli, Zejula, Shingrix |
| Genmab U.S., INC. | $49.73 | 2024-2025 | Epkinly |
| Tempus Ai, INC | $47.33 | 2024 | |
| Janssen Biotech, INC. | $43.49 | 2023-2024 | Talvey, Tecvayli |
| Springworks Therapeutics, INC. | $40.96 | 2025 | Ogsiveo |
| Deciphera Pharmaceuticals INC. | $40.57 | 2024-2025 | Qinlock |
| Gilead Sciences, INC. | $36.63 | 2023-2024 | Trodelvy |
| Rigel Pharmaceuticals, INC. | $34.30 | 2022-2023 | Rezlidhia, Tavalisse |
| Servier Pharmaceuticals LLC | $33.88 | 2022-2024 | |
| Helsinn Therapeutics (U.S.), INC. | $32.48 | 2022 | |
| Immunocore Limited | $25.94 | 2024 | Kimmtrak |
| Agios Pharmaceuticals, INC. | $24.83 | 2023 | Pyrukynd |
| Array Biopharma INC | $24.47 | 2025 | Lorbrena |
| Pharmacyclics LLC, An Abbvie Company | $24.31 | 2023 | Imbruvica |
| Octapharma USA, INC. | $23.82 | 2025 | Octagam Immune Globulin (Human) |
| Karyopharm Therapeutics INC. | $23.45 | 2022 | |
| Organon LLC | $23.23 | 2024 | |
| Celgene Corporation | $22.27 | 2023 | Pomalyst |
| Pharmacosmos Therapeutics INC. | $22.16 | 2024 | Monoferric |
| G1 Therapeutics, INC. | $20.72 | 2022 | |
| Genzyme Corporation | $19.91 | 2024 | |
| Adc Therapeutics America, INC. | $19.52 | 2024 | |
| Puma Biotechnology, INC. | $18.90 | 2022 | |
| Seagen INC. | $18.22 | 2023 | Padcev |
| Kite Pharma, INC. | $17.80 | 2024 | Yescarta |
| Apellis Pharmaceuticals, INC. | $17.51 | 2022 | |
| Foundation Medicine, INC. | $15.66 | 2023 | |
| Pfizer INC. | $15.21 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.24 | 2024 | |
| Sumitomo Pharma America, INC. | $14.05 | 2023 | Orgovyx |
| Stemline Therapeutics INC. | $13.49 | 2023 | Orserdu |
| Aveo Pharmaceuticals, INC. | $12.91 | 2023 | Fotivda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Callie Seybert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.